bioLytical Participates in Glasgow HIV Drug Therapy Congress

Richmond, British Columbia (ots/PRNewswire) -

bioLytical Laboratories, a world leader in rapid infectious
disease tests, is proud to have participated in the HIV Drug Therapy
Congress (http://hivglasgow.org/) which just wrapped up in Glasgow.

This annual Congress brought together key opinion leaders, global
HIV/AIDS programme directors, researchers, physicians, community
health representatives, industry and other stakeholders to share
developments and new ideas in HIV treatment and prevention. The focus
was on ending the HIV/AIDS pandemic, and perspectives from all
sectors in this global effort, including developing world
participants, pediatric treatment specialists, and innovative testing
program leaders were openly featured at this Congress.

The rise of self-testing as a recognized HIV testing strategy in
low and middle income countries is important in achieving the UNAIDS
90-90-90 (http://www.unaids.org/en/resources/documents/2014/90-90-90)
program goals. bioLytical is a leader in the emergence of HIV
self-testing and participated in active discussions with stakeholders
in public and private sectors, along with global donor programmes,
while at the Glasgow Congress.

"We are extremely pleased to see the widespread and growing
acceptance of HIV self-testing as a revolutionary new concept in
reaching key populations." says bioLytical's Chief Technical Officer,
Rick Galli. "We are proud to be introducing the INSTI HIV Self Test
(http://www.insti-hivselftest.com/) next month in Europe and Sub
Saharan Africa. We believe it will play an important role in
identifying previously undiagnosed individuals and facilitating
linkage to care."

About bioLytical Laboratories Inc.

bioLytical Laboratories Inc. is a privately owned Canadian company
engaged in the research, development and commercialization of rapid,
point of care in vitro medical diagnostics using its proprietary
INSTI technology platform. With a world-wide footprint of regulatory
approvals including US FDA approval, Health Canada approval and CE
mark, bioLytical markets and sells its INSTI HIV test globally and
INSTI HIV/Syphilis Multiplex test in Europe. The INSTI product line
provides highly accurate test results in 60 seconds or less, far
faster than the 15-20 minutes required for competitors' tests based
on lateral flow technology. bioLytical has an active R&D program
with a pipeline that includes tests for diseases such as Zika,
Hepatitis C and Ebola, among others. The company also provides
contract services to adapt the INSTI platform to meet custom
functional and technical diagnostic testing requirements. For more
information, please visit http://www.biolytical.com.

Stan Miele, info@biolytical.com , +1-604-204-6784

ots Originaltext: bioLytical Laboratories
Im Internet recherchierbar: http://www.presseportal.de

Original-Content von: bioLytical Laboratories, übermittelt durch news aktuell